Skip to main page content
Home
OnlineFirst
Current Issue
Past Issues
Subscriptions
Alerts
Feedback
AACR Publications
AACR Home
Search
GO
Advanced Search
User Name
Password
Sign In
This item requires a subscription to Clinical Cancer Research.
Full Text
Cancer Therapy: Preclinical
:
Tumor Growth Inhibition by Olaparib in
BRCA2
Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Ursula Kortmann
,
Jessica N. McAlpine
,
Hui Xue
,
Jun Guan
,
Gavin Ha
,
Sophie Tully
,
Sharaz Shafait
,
Alan Lau
,
Aaron N. Cranston
,
Mark J. O'Connor
,
David G. Huntsman
,
Yuzhuo Wang
,
and
C. Blake Gilks
Clin Cancer Res
February 15, 2011
17
:
783
-
791
;
doi:
10.1158/1078-0432.CCR-10-1382
Abstract
Full Text
Full Text (PDF)
Supplementary Data
To view this item, select one of the options below:
Sign In
Sign In
User Name
Password
Remember my user name & password.
Forgot
your user name or password?
Can't get past this page?
Help with Cookies.
Need to Activate?
Purchase Short-Term Access
Pay per Article
- You may access
this article
(from the computer you are currently using) for 1
day
for US$35.00.
Pay for Admission
- You may access
all content in Clinical Cancer Research
(from the computer you are currently using) for 1
day
for US$50.00.
Regain Access
- You can regain access to a recent Pay per Article or Pay for Admission purchase if your access period has not yet expired.
Sign Up
Subscribe to the Journal
- Subscribe to the print and/or online journal.
This Article
doi:
10.1158/1078-0432.CCR-10-1382
Clin Cancer Res
February 15, 2011
17;
783
Abstract
Free
»
Full Text
Full Text (PDF)
Supplementary Data
All Versions of this Article:
1078-0432.CCR-10-1382v1
1078-0432.CCR-10-1382v2
17/4/783
most recent
Classifications
Cancer Therapy: Preclinical
Services
Email this article to a colleague
Alert me when this article is cited
Alert me if a correction is posted
Similar articles in this journal
Similar articles in PubMed
Download to citation manager
Citing Articles
Load citing article information
Citing articles via Scopus
Google Scholar
Articles by Kortmann, U.
Articles by Gilks, C. B.
Search for related content
PubMed
PubMed citation
Articles by Kortmann, U.
Articles by Gilks, C. B.
Current Issue
June 15, 2011, 17 (12)
Alert me to new issues of Clinical Cancer Research
About the Journal
Instructions for Authors/ Submit Manuscript
Editorial Board
Information for Librarians
Information for Readers/ Subscribers
Information for Advertisers
Permissions & Reprints
E-mail Alerts & RSS Feeds [Free]
Feedback
Cancer Discovery
Cancer Research
Cancer Epidemiology Biomarkers & Prevention
Molecular Cancer Therapeutics
Molecular Cancer Research
Cancer Prevention Research
Cancer Prevention Journals Portal
Cancer Reviews Online
Annual Meeting Education Book
Meeting Abstracts Online
Help
Most
Read
Hyperthermic Isolated Limb Perfusion with Tumor Necrosis Factor-{{alpha}} and Melphalan in Patients with Locally Advanced Soft Tissue Sarcomas: Treatment Response and Clinical Outcome Related to Changes in Proliferation and Apoptosis
Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 {{alpha}}, Neuregulin-1 {{beta}}, and Betacellulin, in Normal Endometrium and Endometrial Cancer
Consideration of QT/QTc Interval Data in a Phase I Study in Patients with Advanced Cancer
Imaging of Soft-Tissue Tumors Using L-3-[Iodine-123]Iodo-{{alpha}}-methyl-tyrosine Single Photon Emission Computed Tomography: Comparison with Proliferative and Mitotic Activity, Cellularity, and Vascularity
Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers
» View all Most Read articles
Cited
Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor
Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor
» View all Most Cited articles